Parkinsonian Disorders in Clinical Practice (eBook, PDF)
Redaktion: Schapira, Anthony; Agid, Yves; Hartmann, Andreas
68,99 €
68,99 €
inkl. MwSt.
Sofort per Download lieferbar
0 °P sammeln
68,99 €
Als Download kaufen
68,99 €
inkl. MwSt.
Sofort per Download lieferbar
0 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
68,99 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
0 °P sammeln
Parkinsonian Disorders in Clinical Practice (eBook, PDF)
Redaktion: Schapira, Anthony; Agid, Yves; Hartmann, Andreas
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book gives the reader an up-to-date, clear and logical idea of what caring for parkinsonian patients entails - a challenge that clinicians will face for many years to come. It is split into three sections: Section 1: A compilation of the major brain lesions typically seen in PD Section 2: Treatment options in PD Section 3: 25 cases designed to test the reader and the practical application of the information supplied in the other sections.
- Geräte: PC
- mit Kopierschutz
- eBook Hilfe
- Größe: 1.81MB
Andere Kunden interessierten sich auch für
- Non-Parkinsonian Movement Disorders (eBook, PDF)63,99 €
- Belinda DaughrityAutism Spectrum Disorders from Theory to Practice (eBook, PDF)45,00 €
- Peripheral Nerve Disorders (eBook, PDF)150,99 €
- Multiple Sclerosis and CNS Inflammatory Disorders (eBook, PDF)70,99 €
- Evidence-based Dementia Practice (eBook, PDF)208,99 €
- Therapeutics of Parkinson's Disease and Other Movement Disorders (eBook, PDF)143,99 €
- Neuroimmunology in Clinical Practice (eBook, PDF)167,99 €
-
-
-
This book gives the reader an up-to-date, clear and logical idea of what caring for parkinsonian patients entails - a challenge that clinicians will face for many years to come. It is split into three sections: Section 1: A compilation of the major brain lesions typically seen in PD Section 2: Treatment options in PD Section 3: 25 cases designed to test the reader and the practical application of the information supplied in the other sections.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: John Wiley & Sons
- Seitenzahl: 208
- Erscheinungstermin: 27. April 2009
- Englisch
- ISBN-13: 9781444306392
- Artikelnr.: 38307102
- Verlag: John Wiley & Sons
- Seitenzahl: 208
- Erscheinungstermin: 27. April 2009
- Englisch
- ISBN-13: 9781444306392
- Artikelnr.: 38307102
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Anthony HV Schapira, MD DSC, FRCP, FMedSci, Professor and Head of Department University College of Clinical Neurosciences, Institute of Neurology, University College London, Queen Square, London UK. Professor of Neurology, National Hospital for Neurology and Neurosurgery and Roayl Free Hospital, London, UK. Andreas Hartmann, MD, Clinical Investigation Center, Pitie-Salpetriere Hopital, Paris, France. Federation of Nervous System Disease, Pitie-Salpetriere Hopital, Paris, France. National Institute of Health and Medical Research, Paris, France. Pierre and MAric Curie University,?Paris, France. Yves Agid, MD, PhD, Clinical Investigation Center, Pitie-Salpetriere Hopital, Paris, France. Federation of Nervous System Disease, Pitie-Salpetriere Hopital, Paris, France. National Institute of Health and Medical Research, Paris, France. Pierre and MAric Curie University,?Paris, France.
Preface.
Introduction.
1 What is Parkinson's disease? From pathophysiology to symptoms (Andreas
Hartmann, Yves Agid, Anthony Schapira).
I. Pathophysiology of Parkinson's disease.
1. Dysfunctions of the main neuronal pathways in Parkinson's disease.
a. An overview of neuronal systems affected in Parkinson's disease.
b. Dopaminergic neurons.
c. Non-dopaminergic neurons.
2. Consequences of dopaminergic neuronal lesions on basal ganglia circuits.
a. The dopaminergic nigrostriatal system: pre- and postsynaptic
compensatory mechanisms.
b. Pathologic alterations of nigrostriatal circuits in Parkinson's disease.
3. Histopathology of Parkinson's disease.
4. The etiopathogenesis of Parkinson's disease.
a. The genetics of Parkinson's disease: any clues for the sporadic forms?
b. Relevant environmental factors: focus on mitochondria.
c. Mechanisms of cell death in Parkinson's disease: therapeutic
implications.
5. Conclusions.
a. Parkinson's disease or Parkinson's syndromes?
b. What Parkinson's disease is not.
II. Clinical features of Parkinson's disease.
1. Motor symptoms.
2. Non-motor symptoms.
a. Depression.
b. Apathy.
c. Cognitive impairment.
d. Sleep.
e. Autonomic dysfunction.
f. Sensory symptoms.
3. The different forms of Parkinson's disease: relevance for prognosis.
4. The differential diagnosis of Parkinson's disease.
5. Treatment-related symptoms.
a. Motor complications.
b. Non-motor complications.
2 Treatment of Parkinson's disease (Anthony Schapira, Andreas Hartmann,
Yves Agid).
I. Antiparkinsonian agents.
1. Levodopa.
2. COMT inhibitors.
3. Dopamine agonists.
4. Monoamine oxidase B inhibitors.
5. Other drugs.
II. Medical management.
1. Initiation of treatment.
2. Maintenance of treatment (Fig. 2.7).
3. Motor complications.
4. Management of non-motor complications.
III. Non-medical management.
1. Surgery.
2. Destructive lesions.
3. Cell therapy.
4. Growth factors.
IV. Neuroprotection.
1. MAO-B inhibitors.
2. Dopamine agonists.
3. Coenzyme Q.
4. Creatine.
5. Antiapoptotic drugs.
V. Conclusion.
3 Case studies.
Case studies-diagnostic index.
Index.
Introduction.
1 What is Parkinson's disease? From pathophysiology to symptoms (Andreas
Hartmann, Yves Agid, Anthony Schapira).
I. Pathophysiology of Parkinson's disease.
1. Dysfunctions of the main neuronal pathways in Parkinson's disease.
a. An overview of neuronal systems affected in Parkinson's disease.
b. Dopaminergic neurons.
c. Non-dopaminergic neurons.
2. Consequences of dopaminergic neuronal lesions on basal ganglia circuits.
a. The dopaminergic nigrostriatal system: pre- and postsynaptic
compensatory mechanisms.
b. Pathologic alterations of nigrostriatal circuits in Parkinson's disease.
3. Histopathology of Parkinson's disease.
4. The etiopathogenesis of Parkinson's disease.
a. The genetics of Parkinson's disease: any clues for the sporadic forms?
b. Relevant environmental factors: focus on mitochondria.
c. Mechanisms of cell death in Parkinson's disease: therapeutic
implications.
5. Conclusions.
a. Parkinson's disease or Parkinson's syndromes?
b. What Parkinson's disease is not.
II. Clinical features of Parkinson's disease.
1. Motor symptoms.
2. Non-motor symptoms.
a. Depression.
b. Apathy.
c. Cognitive impairment.
d. Sleep.
e. Autonomic dysfunction.
f. Sensory symptoms.
3. The different forms of Parkinson's disease: relevance for prognosis.
4. The differential diagnosis of Parkinson's disease.
5. Treatment-related symptoms.
a. Motor complications.
b. Non-motor complications.
2 Treatment of Parkinson's disease (Anthony Schapira, Andreas Hartmann,
Yves Agid).
I. Antiparkinsonian agents.
1. Levodopa.
2. COMT inhibitors.
3. Dopamine agonists.
4. Monoamine oxidase B inhibitors.
5. Other drugs.
II. Medical management.
1. Initiation of treatment.
2. Maintenance of treatment (Fig. 2.7).
3. Motor complications.
4. Management of non-motor complications.
III. Non-medical management.
1. Surgery.
2. Destructive lesions.
3. Cell therapy.
4. Growth factors.
IV. Neuroprotection.
1. MAO-B inhibitors.
2. Dopamine agonists.
3. Coenzyme Q.
4. Creatine.
5. Antiapoptotic drugs.
V. Conclusion.
3 Case studies.
Case studies-diagnostic index.
Index.
Preface.
Introduction.
1 What is Parkinson's disease? From pathophysiology to symptoms (Andreas
Hartmann, Yves Agid, Anthony Schapira).
I. Pathophysiology of Parkinson's disease.
1. Dysfunctions of the main neuronal pathways in Parkinson's disease.
a. An overview of neuronal systems affected in Parkinson's disease.
b. Dopaminergic neurons.
c. Non-dopaminergic neurons.
2. Consequences of dopaminergic neuronal lesions on basal ganglia circuits.
a. The dopaminergic nigrostriatal system: pre- and postsynaptic
compensatory mechanisms.
b. Pathologic alterations of nigrostriatal circuits in Parkinson's disease.
3. Histopathology of Parkinson's disease.
4. The etiopathogenesis of Parkinson's disease.
a. The genetics of Parkinson's disease: any clues for the sporadic forms?
b. Relevant environmental factors: focus on mitochondria.
c. Mechanisms of cell death in Parkinson's disease: therapeutic
implications.
5. Conclusions.
a. Parkinson's disease or Parkinson's syndromes?
b. What Parkinson's disease is not.
II. Clinical features of Parkinson's disease.
1. Motor symptoms.
2. Non-motor symptoms.
a. Depression.
b. Apathy.
c. Cognitive impairment.
d. Sleep.
e. Autonomic dysfunction.
f. Sensory symptoms.
3. The different forms of Parkinson's disease: relevance for prognosis.
4. The differential diagnosis of Parkinson's disease.
5. Treatment-related symptoms.
a. Motor complications.
b. Non-motor complications.
2 Treatment of Parkinson's disease (Anthony Schapira, Andreas Hartmann,
Yves Agid).
I. Antiparkinsonian agents.
1. Levodopa.
2. COMT inhibitors.
3. Dopamine agonists.
4. Monoamine oxidase B inhibitors.
5. Other drugs.
II. Medical management.
1. Initiation of treatment.
2. Maintenance of treatment (Fig. 2.7).
3. Motor complications.
4. Management of non-motor complications.
III. Non-medical management.
1. Surgery.
2. Destructive lesions.
3. Cell therapy.
4. Growth factors.
IV. Neuroprotection.
1. MAO-B inhibitors.
2. Dopamine agonists.
3. Coenzyme Q.
4. Creatine.
5. Antiapoptotic drugs.
V. Conclusion.
3 Case studies.
Case studies-diagnostic index.
Index.
Introduction.
1 What is Parkinson's disease? From pathophysiology to symptoms (Andreas
Hartmann, Yves Agid, Anthony Schapira).
I. Pathophysiology of Parkinson's disease.
1. Dysfunctions of the main neuronal pathways in Parkinson's disease.
a. An overview of neuronal systems affected in Parkinson's disease.
b. Dopaminergic neurons.
c. Non-dopaminergic neurons.
2. Consequences of dopaminergic neuronal lesions on basal ganglia circuits.
a. The dopaminergic nigrostriatal system: pre- and postsynaptic
compensatory mechanisms.
b. Pathologic alterations of nigrostriatal circuits in Parkinson's disease.
3. Histopathology of Parkinson's disease.
4. The etiopathogenesis of Parkinson's disease.
a. The genetics of Parkinson's disease: any clues for the sporadic forms?
b. Relevant environmental factors: focus on mitochondria.
c. Mechanisms of cell death in Parkinson's disease: therapeutic
implications.
5. Conclusions.
a. Parkinson's disease or Parkinson's syndromes?
b. What Parkinson's disease is not.
II. Clinical features of Parkinson's disease.
1. Motor symptoms.
2. Non-motor symptoms.
a. Depression.
b. Apathy.
c. Cognitive impairment.
d. Sleep.
e. Autonomic dysfunction.
f. Sensory symptoms.
3. The different forms of Parkinson's disease: relevance for prognosis.
4. The differential diagnosis of Parkinson's disease.
5. Treatment-related symptoms.
a. Motor complications.
b. Non-motor complications.
2 Treatment of Parkinson's disease (Anthony Schapira, Andreas Hartmann,
Yves Agid).
I. Antiparkinsonian agents.
1. Levodopa.
2. COMT inhibitors.
3. Dopamine agonists.
4. Monoamine oxidase B inhibitors.
5. Other drugs.
II. Medical management.
1. Initiation of treatment.
2. Maintenance of treatment (Fig. 2.7).
3. Motor complications.
4. Management of non-motor complications.
III. Non-medical management.
1. Surgery.
2. Destructive lesions.
3. Cell therapy.
4. Growth factors.
IV. Neuroprotection.
1. MAO-B inhibitors.
2. Dopamine agonists.
3. Coenzyme Q.
4. Creatine.
5. Antiapoptotic drugs.
V. Conclusion.
3 Case studies.
Case studies-diagnostic index.
Index.